Degraders of kelch-like ech-associated protein 1 (keap1)
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael Gray, Tinghu Zhang, Guangyan Du, Nathaniel Henning, Jie Jiang, Eric Fischer, Katherine Donovan
Life of this patent
Estimating the term…
Abstract
The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by Kelch-like ECH-associated protein 1 (KEAP1). In some aspects, the present invention is directed to methods of treating diseases or disorders involving dysfunctional (e.g., dysregulated) KEAP1 activity, that entails administration of a therapeutically effective amount of a bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.
Claims25
A bifunctional compound having a structure represented by formula:
- wherein the degron represents a moiety that binds an E3 ubiquitin ligase, and the linker represents a moiety that covalently connects the degron and the targeting ligand, or a pharmaceutically acceptable salt or stereoisomer thereof,
- wherein the KEAP1 targeting ligand is represented by formula TL1a or TL1b:
- wherein:
- R1 represents optionally substituted C1-C3 alkyl;
- R2 represents Me, OMe, or halo;
- R3 represents Me, OMe, or halo;
- X represents H and Y represents optionally substituted C1-C3 alkyl, or
- X represents O and Y represents optionally substituted CH2—CH2 and X and Y together with the atoms to which they are bound form a 7-membered cyclic sulfonamide;
- Ar represents a benzene or pyridine ring, or
- wherein the KEAP1 targeting ligand is represented by formula (TL2):
- wherein:
- R4 represents optionally substituted C1-C3 alkyl, OMe, or halo, or
- wherein the KEAP1 targeting ligand is represented by formula (TL3):
- wherein:
- R5 represents optionally substituted C1-C3 alkyl.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.